Apollomics, Inc. (APLMW) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Apollomics, Inc. (APLMW) trades at $0.0158 with AI Score 59/100 (Grade B). Apollomics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of oncology therapies. Market cap: $234M, Sector: Financial services.
Price as of Aug 20, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for APLMW: APLMW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates APLMW against Financial Services peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
APLMW: the 3 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Apollomics, Inc. (APLMW) Financial Services Profile
Apollomics, Inc., a clinical-stage biotechnology firm, specializes in oncology therapy discovery and development. Operating within the financial services sector, the company targets unmet medical needs in oncology. With a negative profit margin and a high beta, Apollomics faces significant market volatility and financial challenges in a competitive landscape.
What Is the Investment Thesis for APLMW?
Investing in Apollomics, Inc. presents a high-risk, high-reward scenario. The company's focus on oncology therapies addresses a significant market need, but its current financial metrics raise concerns. With a market capitalization of $234M and a negative P/E ratio of -0.69, the company's valuation is highly speculative. Key value drivers include successful clinical trial outcomes and potential FDA approvals for its drug candidates. Growth catalysts involve securing partnerships with larger pharmaceutical companies and expanding its pipeline through strategic acquisitions or licensing agreements. However, potential risks include clinical trial failures, regulatory hurdles, and the need for substantial additional funding to sustain operations. The high beta of 1.76 indicates significant market volatility.
Based on FMP financials and quantitative analysis
APLMW Key Highlights
Market Cap of $234M reflects the company's current valuation in the biotechnology sector.
- Negative P/E ratio of -0.69 indicates that the company is not currently profitable.
- Profit Margin of -450.0% highlights the significant expenses associated with research and development in the biotechnology industry.
- Gross Margin of -22.7% suggests challenges in generating revenue relative to the cost of goods sold.
- Beta of 1.76 indicates higher volatility compared to the overall market, reflecting the speculative nature of biotechnology stocks.
Who Are APLMW's Competitors?
APLMW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| FGMC FG Merger Corp. | $8.30 | +0.00% | $85.5M | 47 |
| IRHO Iron Horse Acquisitions II Corp. Common Stock | $10.03 | +0.00% | $235M | 48 |
| ADAC American Drive Acquisition Company Class A Ordinary Shares | $10.09 | -0.10% | $232M | 49 |
| BLRK Bluerock Acquisition Corp. Class A Ordinary Shares | $10.06 | +0.05% | $232M | 62 |
| VHCP Vine Hill Capital Investment Corp. II Class A Ordinary Shares | $10.05 | +0.30% | $231M | 64 |
| ITHA ITHA | $10.03 | +0.00% | $231M | 54 |
| MEVOU M Evo Global Acquisition Corp II Units | $10.16 | +0.39% | $229M | 61 |
| XCBEU XCBEU | $10.09 | +0.00% | $227M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are APLMW's Key Strengths?
Focus on oncology, a high-growth market.
- Proprietary drug development pipeline.
- Experienced leadership team.
- Potential for breakthrough therapies.
What Are APLMW's Weaknesses?
Negative profit margin and gross margin.
- Reliance on external funding.
- Small number of employees.
- Limited commercialization experience.
What Could Drive APLMW Stock Higher?
Clinical trial results for lead drug candidate.
- Potential FDA approval of lead drug candidate.
- Strategic partnerships with pharmaceutical companies.
- Expansion of drug pipeline through acquisitions or licensing.
What Are the Key Risks for APLMW?
Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from larger pharmaceutical companies.
- Need for additional funding to sustain operations.
What Are the Growth Opportunities for APLMW?
- Expansion of Drug Pipeline: Apollomics has the opportunity to expand its pipeline of oncology therapies through internal research and development efforts, as well as strategic acquisitions or licensing agreements. The global oncology market is projected to reach $300 billion by 2028, providing a substantial market opportunity for new and innovative treatments. Successful expansion of the pipeline could lead to increased investor confidence and higher valuation multiples.
- Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies could provide Apollomics with access to additional funding, expertise, and resources to accelerate the development and commercialization of its drug candidates. Such partnerships could also validate the company's technology and increase its visibility within the industry. The timeline for securing these partnerships is dependent on successful clinical trial outcomes and regulatory milestones.
- FDA Approval of Lead Drug Candidate: Securing FDA approval for its lead drug candidate would be a major catalyst for Apollomics, validating its research and development efforts and opening up a significant revenue stream. The approval process typically takes several years and involves multiple phases of clinical trials. Successful approval would likely lead to a significant increase in the company's stock price and market capitalization.
- Advancements in Personalized Medicine: The growing trend towards personalized medicine offers Apollomics the opportunity to develop targeted therapies that are tailored to individual patients based on their genetic profiles or other biomarkers. This approach could lead to more effective treatments and improved patient outcomes. The market for personalized medicine is expected to grow rapidly in the coming years, driven by advancements in genomics and diagnostics.
- Global Expansion: Apollomics could expand its geographic reach by targeting markets outside of the United States, such as Europe and Asia. These markets offer significant growth potential, particularly in countries with rapidly aging populations and increasing rates of cancer. However, global expansion would require significant investment in infrastructure and regulatory compliance.
What Are APLMW's Competitive Advantages?
- Proprietary drug candidates in development.
- Expertise in oncology research and development.
- Intellectual property protection for its therapies.
What Does APLMW Do?
Founded in 2015 by Liang Yu Guo and Sanjeev Redkar, Apollomics, Inc. is a clinical-stage biotechnology company headquartered in Foster City, California. The company is dedicated to the discovery and development of innovative oncology therapies designed to address critical unmet medical needs in cancer treatment. Apollomics focuses on identifying and developing novel therapeutic candidates that can improve patient outcomes and quality of life. Since its inception, Apollomics has been committed to advancing the field of oncology through rigorous research and development efforts. The company's strategy involves a combination of internal research programs and strategic collaborations to expand its pipeline of potential drug candidates. Apollomics operates with a team of 13 employees, indicating a lean and focused approach to its research and development activities. The company's financial performance reflects the challenges inherent in the biotechnology industry, with a negative profit margin of -450.0% and a gross margin of -22.7%. These figures highlight the significant investments required in research and clinical trials before potential revenue generation from successful therapies.
What Products and Services Does APLMW Offer?
- Discovers and develops oncology therapies.
- Focuses on addressing unmet medical needs in cancer treatment.
- Conducts research and development to identify novel therapeutic candidates.
- Engages in clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approvals for its therapies from agencies like the FDA.
- Potentially commercializes approved therapies through partnerships or internal sales efforts.
How Does APLMW Make Money?
- Develops oncology therapies through internal research and development.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through milestone payments and royalties from partnered products.
What Industry Does APLMW Operate In?
Apollomics, Inc. operates within the highly competitive biotechnology industry, which is characterized by intense research and development efforts, stringent regulatory requirements, and significant financial risks. The oncology segment of the biotechnology market is particularly crowded, with numerous companies vying to develop innovative cancer therapies. Market trends include a growing emphasis on personalized medicine, targeted therapies, and immunotherapy approaches. Apollomics' success depends on its ability to differentiate its drug candidates and navigate the complex regulatory landscape. Competitors include both large pharmaceutical companies with established oncology portfolios and smaller biotechnology firms focused on specific cancer targets.
Who Are APLMW's Key Customers?
- Pharmaceutical companies seeking to expand their oncology portfolios.
- Patients with cancer who may benefit from new therapies.
- Healthcare providers who prescribe and administer cancer treatments.
Apollomics, Inc. (APLMW) Valuation Context
Valued at $234M, APLMW is classified as a micro-cap stock. Relative to its peer group, APLMW's quantitative score of 59/100 is roughly in line with the peer average of 54/100.
APLMW Revenue & Earnings Trend
In Q2 2025, APLMW generated $8.5M in top-line revenue, marking a sequential increase of 380.8%. The company recorded a net loss of $12.5M, with diluted EPS of $-11.37.
Company Profile
Apollomics, Inc. operates in the Financial - Conglomerates industry within the Financial Services sector. It is headquartered in Foster City, US. The company is led by CEO Guo-Liang Yu. APLMW has traded publicly since 2023.
Key Financial Metrics
Return on equity for Apollomics, Inc. stands at 288.4%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -20.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.96 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -110.1%, the inverse of the P/E and a quick read on earnings relative to price.
Forward Outlook
Wall Street analysts project Apollomics, Inc. revenue of about $0 for fiscal 2026, with EPS near $-122.00.
APLMW Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Focus on oncology, a high-growth market.
- Proprietary drug development pipeline.
- Experienced leadership team.
- Potential for breakthrough therapies.
Bear Case
- Negative profit margin and gross margin.
- Reliance on external funding.
- Small number of employees.
- Limited commercialization experience.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $9M | -$13M | -$11.37 |
| Q2 2024 | $2M | -$35M | -$38.00 |
Based on FMP financials and quantitative analysis
APLMW Latest News
No recent news available for APLMW.
APLMW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for APLMW.
Price Targets
Wall Street price target analysis for APLMW.
APLMW MoonshotScore
What does this score mean?
The MoonshotScore rates APLMW 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Guo-Liang Yu
CEO
Guo-Liang Yu is the CEO of Apollomics, Inc. He co-founded the company in 2015 with Sanjeev Redkar. His background includes extensive experience in the biotechnology industry, with a focus on oncology drug development. He has held leadership positions in various pharmaceutical and biotechnology companies, contributing to the development and commercialization of several successful cancer therapies. His expertise spans research, clinical development, and business strategy.
Track Record: Under Guo-Liang Yu's leadership, Apollomics has advanced several drug candidates into clinical trials. He has overseen the company's strategic partnerships and fundraising efforts. Key milestones include securing funding for clinical trials and expanding the company's pipeline through licensing agreements. His focus has been on building a strong team and fostering a culture of innovation within the company.
Apollomics, Inc. Financial Services Stock: Key Questions Answered
What does the AI Score mean for APLMW?
APLMW holds an AI Score of 59/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Apollomics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of oncology therapies. The company addresses unmet medical needs in the oncology space.
What does Apollomics, Inc. do?
Apollomics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of oncology therapies. The company aims to address unmet medical needs in cancer treatment by identifying and developing novel therapeutic candidates. Apollomics operates primarily in the research and development phase, seeking to advance its drug candidates through clinical trials and regulatory approvals.
What do analysts say about APLMW stock?
Analyst coverage of Apollomics, Inc. (APLMW) is limited due to its size and stage of development. However, the consensus view is that the company's success hinges on the outcome of its clinical trials and regulatory approvals. Key valuation metrics include the potential market size of its drug candidates and the likelihood of successful commercialization.
What are the main risks for APLMW?
The main risks for Apollomics, Inc. include clinical trial failures, which could significantly impact the company's valuation and future prospects. Regulatory hurdles and delays in obtaining FDA approval also pose a significant risk. Competition from larger pharmaceutical companies with greater resources and established oncology portfolios is another key concern.
What are the key factors to evaluate for APLMW?
Apollomics, Inc. (APLMW) holds an AI score of 59/100 (moderate). Investing in Apollomics, Inc. presents a high-risk, high-reward scenario. Not financial advice.
How frequently does APLMW data refresh on this page?
APLMW's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven APLMW's recent stock price performance?
Apollomics, Inc. (APLMW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on oncology, a high-growth market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider APLMW overvalued or undervalued right now?
Apollomics, Inc. (APLMW) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research APLMW before investing?
Before investing in Apollomics, Inc. (APLMW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date.
- Analyst coverage is sparse, leading to uncertainty in consensus estimates.
- The biotechnology industry is inherently risky, with a high failure rate for drug development.